Evidence map›Paper›PMID 41764167›Full record

ArticleTranslational psychiatry2026

Common and rare variant contributions to discontinuation of stimulant treatment in ADHD.

Janne Pia Thirstrup, Jinjie Duan, Marta Ribases Haro, Maria Soler Artigas, Clara Albiñana, Søren Dalsgaard, Stephen V Faraone, Thomas Werge, Jonas Bybjerg-Grauholm, Anders D Børglum and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Janne Pia ThirstrupDepartment of Biomedicine, Aarhus University, 8000, Aarhus C, Denmark.
Jinjie DuanDepartment of Biomedicine, Aarhus University, 8000, Aarhus C, Denmark.ORCID http://orcid.org/0000-0002-3402-302X
Marta Ribases HaroPsychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0003-1039-1116
Maria Soler ArtigasPsychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-3213-1107
Clara AlbiñanaThe Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark.
Søren DalsgaardNational Centre for Register-based Research, Department of Public Health, Aarhus University, Aarhus, Denmark.ORCID http://orcid.org/0000-0003-4659-0969
Stephen V FaraoneDepartments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY, USA.ORCID http://orcid.org/0000-0002-9217-3982
Thomas WergeThe Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark.ORCID http://orcid.org/0000-0003-1829-0766
Jonas Bybjerg-GrauholmDepartment for Congenital Disorders at the Statens Serum Institut (SSI), Copenhagen S, Denmark.ORCID http://orcid.org/0000-0003-1705-4008
Anders D BørglumDepartment of Biomedicine, Aarhus University, 8000, Aarhus C, Denmark.ORCID http://orcid.org/0000-0001-8627-7219
Esben AgerboThe Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark.
Honghui YaoDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Zheng ChangDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Isabell Brikell *Department of Biomedicine, Aarhus University, 8000, Aarhus C, Denmark.
Ditte Demontis *Department of Biomedicine, Aarhus University, 8000, Aarhus C, Denmark. ditte@biomed.au.dk.ORCID http://orcid.org/0000-0001-9124-2766

Funding

Novo Nordisk Fonden (Novo Nordisk Foundation) NNF20OC0065561
6 · The paper itself

Abstract

Stimulants are the first-line pharmacological treatment for ADHD and generally effective, yet 35-61% of individuals discontinue treatment within a year. We investigated the contribution of common and rare genetic variants to early stimulant discontinuation using data from 18,362 individuals with ADHD (31% female) initiating stimulants in iPSYCH, a Danish population-based case-cohort linked to national registers. Discontinuation was defined as a ≥ 180-day gap between dispensations within one year of initiation. We examined genetic differences by age groups, estimated SNP-heritability (h

Indexed as

Attention Deficit Disorder with HyperactivityCentral Nervous System StimulantsAdolescentChildDenmarkFemaleGenetic Risk ScoreGenetic VariationGenome-Wide Association StudyHumansMalePolymorphism, Single NucleotideRegistriesCentral Nervous System Stimulants

Identifiers

PMID41764167
PMCPMC12987951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.